| Dr David Karl Drill, MD | |
|
3840 Rimrock Rd, #3111, Billings, MT 59102-0100 | |
| (406) 655-5376 | |
| Not Available |
| Full Name | Dr David Karl Drill |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 3840 Rimrock Rd, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255698106 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 3131 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Karl Drill, MD 3840 Rimrock Rd, #3111, Billings, MT 59102-0100 Ph: (406) 655-5376 | Dr David Karl Drill, MD 3840 Rimrock Rd, #3111, Billings, MT 59102-0100 Ph: (406) 655-5376 |
News Archive
In FDLI's latest monograph, Selling Pharmaceuticals and Biologics to the Federal Government: Federal Supply Schedule and Federal Pricing Requirements, Joy Sturm, Allison Pugsley and Stephen A. Smyers of Hogan Lovells US LLP detail how pharmaceutical and biologics manufacturers can deal effectively with government contracting requirements and price calculation requirements.
At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research at Washington University School of Medicine in St. Louis.
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced an agreement to extend the research collaboration with Professor Knud J. Jensen at the Faculty of Life Sciences, University of Copenhagen, to develop new applications on the Biotage Syro Wave in the field of synthetic peptide and protein chemistry. The collaboration builds on Professor Jensen's previous research in developing novel chemistries for and applications of solid-phase peptide synthesis.
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
› Verified 5 days ago
Charles Wittnam, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2675 Central Ave, Billings, MT 59102 Phone: 406-238-2500 | |
Phillip Embury Griffin, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2938 Rockrim Ln, Billings, MT 59102 Phone: 406-259-7582 | |
Megan B Littlefield, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Charles Mcclave, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N, Suite 160w, Billings, MT 59101 Phone: 406-237-8500 Fax: 406-237-8501 | |
Karen C. Klee, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Brock P. Whittenberger, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Benjamin Girton Plank, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |